2005
PD-083 Pemetrexed (P) plus carboplatin (Cb) as 1st treatment for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC): Results of both a multi-center European and an MD Anderson Cancer Center (MDACC) phase II trials
Zinner R, Kortsik C, Dark G, Price A, Manegold C, Rosell R, Paz-Ares L, Herbst R, Crino L, Scagliotti G. PD-083 Pemetrexed (P) plus carboplatin (Cb) as 1st treatment for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC): Results of both a multi-center European and an MD Anderson Cancer Center (MDACC) phase II trials. Lung Cancer 2005, 49: s91. DOI: 10.1016/s0169-5002(05)80416-7.Peer-Reviewed Original ResearchO-186 Mutations in EGFR, HER2, KRAS and BRAF in NSCLC: Prevalences and correlations with clinical outcomes in patients treated with carboplatin and paclitaxel with or without erlotinib
Eberhard D, Johnson B, Goddard A, Herbst R, Janne P, Johnson D, Klein P, Ostland M, Seshagiri S, Hillan K. O-186 Mutations in EGFR, HER2, KRAS and BRAF in NSCLC: Prevalences and correlations with clinical outcomes in patients treated with carboplatin and paclitaxel with or without erlotinib. Lung Cancer 2005, 49: s62. DOI: 10.1016/s0169-5002(05)80320-4.Peer-Reviewed Original ResearchPreliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1 st -line treatment in patients with NSCLC
Johnson B, Ma P, West H, Kerr R, Prager D, Sandler A, Herbst R, Stewart D, Dimery I, Heymach J. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1 st -line treatment in patients with NSCLC. Journal Of Clinical Oncology 2005, 23: 7102-7102. DOI: 10.1200/jco.2005.23.16_suppl.7102.Peer-Reviewed Original Research
2004
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC)
Tran H, Zinner R, Blumenschein G, Oh Y, Papadimitrakopoulou V, Kim E, Lu C, Malik M, Lum B, Herbst R. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC). Journal Of Clinical Oncology 2004, 22: 2050-2050. DOI: 10.1200/jco.2004.22.14_suppl.2050.Peer-Reviewed Original ResearchTRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)
Herbst R, Prager D, Hermann R, Miller V, Fehrenbacher L, Hoffman P, Johnson B, Sandler A, Mass R, Johnson D. TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2004, 22: 7011-7011. DOI: 10.1200/jco.2004.22.14_suppl.7011.Peer-Reviewed Original ResearchA phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC)
Koshy S, Herbst R, Obasaju C, Fossella F, Papadimitrakopoulou V, Pisters K, Blumenschein G, Peeples B, Hong W, Zinner R. A phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC). Journal Of Clinical Oncology 2004, 22: 7074-7074. DOI: 10.1200/jco.2004.22.14_suppl.7074.Peer-Reviewed Original ResearchPharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC)
Tran H, Zinner R, Blumenschein G, Oh Y, Papadimitrakopoulou V, Kim E, Lu C, Malik M, Lum B, Herbst R. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC). Journal Of Clinical Oncology 2004, 22: 2050-2050. DOI: 10.1200/jco.2004.22.90140.2050.Peer-Reviewed Original ResearchTRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)
Herbst R, Prager D, Hermann R, Miller V, Fehrenbacher L, Hoffman P, Johnson B, Sandler A, Mass R, Johnson D. TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2004, 22: 7011-7011. DOI: 10.1200/jco.2004.22.90140.7011.Peer-Reviewed Original ResearchA phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC)
Koshy S, Herbst R, Obasaju C, Fossella F, Papadimitrakopoulou V, Pisters K, Blumenschein G, Peeples B, Hong W, Zinner R. A phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC). Journal Of Clinical Oncology 2004, 22: 7074-7074. DOI: 10.1200/jco.2004.22.90140.7074.Peer-Reviewed Original Research
2003
P-522 A phase II trial of Alimta plus carboplatin (AC) in patients (pts) with advanced non-small-cell lung cancer (NSCLC)
Zinner R, Obasaju C, Fossella F, Pisters K, Papadimitrakopoulou V, Varghese B, Peeples B, Hatfield A, Hong W, Herbst R. P-522 A phase II trial of Alimta plus carboplatin (AC) in patients (pts) with advanced non-small-cell lung cancer (NSCLC). Lung Cancer 2003, 41: s223. DOI: 10.1016/s0169-5002(03)92489-5.Peer-Reviewed Original Research